But this can just start. As many companies compete in the market for rival versions of semaglutide in the form of cheaper and take, increasing evidence that GLP-1 drugs can target many health conditions, treatments could have an impact beyond reversing the global trends that lead to rising obesity and possibly alcohol sales. So, what is beyond these drugs? And what is the stumbling block?
This article is part of a special series investigating the GLP-1 agonist boom. Click here for details.
More and more studies have shown that in addition to weight loss, semaglutide appears to have many beneficial effects. For example, in a 4-In a 2019 trial involving nearly 18,000 people, 6.5% of people taking semaglutide had a heart attack or stroke compared to 8% of people receiving a placebo.
Treatment can even reduce cravings in many different types, not just food (see Can GLP-1 drugs really tell you about the brain’s reward system). “There are anecdotal reports of people who significantly reduce their alcohol intake with semaglutide,” he says. Helen Colhoun At the University of Edinburgh, UK. “I think this is one exciting possibility…
Source: www.newscientist.com